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Abstract
The uncoupling protein (UCP) 2 gene is expressed in adipose tissues and skeletal muscles, which are important sites for variations in
energy expenditure. The objective of the current study was to examine the potential impact of a C!T substitution in exon 4, resulting in an
alanine to valine substitution at codon 55, on the Metabolic Syndrome in 284 unrelated Swedish men born in 1944. The subjects were
genotyped using PCR amplification of the exon 4 region of the UCP2 gene followed by digestion with the restriction enzyme EclHK1. The
allelic frequencies were 0.56 for allele Ala and 0.44 for allele Val. No association was found between the Ala55Val SNP and obesity and
blood levels of insulin, glucose, and lipids as well as blood pressure and circulating hormones. From these data, we conclude that the C!T
substitution in exon 4 of the UCP2 gene does not contribute to the predisposition to be affected by the Metabolic Syndrome.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The mitochondrial uncoupling proteins (UCP) are
thought to play an important role in the molecular basis
for energy expenditure. However, the precise function of
these proteins in human metabolism is still unclear [1]. In
newborn infants, UCP1 is potentially a major contributor to
the energy expenditure [1], but is unlikely to be involved in
weight regulation in adult humans. In 1997, two new
mitochondrial UCPs, UCP2 and UCP3, were discovered.
It has been proposed that UCP2 and UCP3 have thermo-
genic properties and that they may thus be involved in
energy metabolism [2,3]. The UCP2–UCP3 gene cluster
maps to 11q13 in humans [4]. A number of single nucleo-
tide polymorphisms (SNPs) in the UCP1, UCP2 and UCP3
genes have been identified, and they have been studied for
linkages and associations with obesity traits [1]. In Pima
Indians, a C!T substitution in exon 4 of the UCP2 gene,
resulting in an alanine to valine substitution at codon 55, has
been found to be associated with metabolic rate during sleep
and over 24 h [4]. In addition, the valine substitution in the
homozygous state exhibits an enhanced metabolic efficiency
and a lower fat oxidation rate [5]. However, several studies
do not support an impact of the UCP2 Ala55Val SNP on
either obesity or Type 2 diabetes [1].
There is a clustering of risk factors, including obesity,
hypertension, glucose intolerance, diabetes mellitus, and
hyperlipidemia, which is observed more frequently in some
individuals than by chance alone. This has led to the
suggestion that this cluster represents a single syndrome,
which has been referred to as the Metabolic Syndrome [6].
Hence, the objective of the present study was to evaluate the
potential impact of the Ala55Val variant of the UCP2 gene
on obesity and blood levels of insulin, glucose, and lipids as
well as blood pressure and circulating hormones, including
salivary cortisol.
2. Subjects and methods
The subjects (n=284) were randomly selected from a
larger geographically defined total population cohort of men
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born in Gothenburg, Sweden in 1944. The design has been
described elsewhere [7]. All subjects gave written informed
consent before participating in the study, which was
approved by the Ethics Committee of Go¨teborg University.
Body mass index (BMI, kg/m2), waist-to-hip ratio
(WHR), and abdominal sagittal diameter were measured
as described previously [7]. Salivary cortisol was measured
repeatedly over a random working day. Endocrine measure-
ments, beside cortisol, included testosterone, insulin-like
growth factor I, and leptin as described previously [7].
Blood levels of insulin, glucose, triglycerides, total, high
(HDL) and low (LDL) density lipoprotein cholesterol were
measured in the overnight fasting state as described pre-
viously [7]. The serum lipids were determined by an
enzymatic procedure in a Cobas Fara II (Roche Molecular
Biochemicals, Mannheim, Germany). Two blood pressure
readings were recorded on the right arm with the partic-
ipants sitting, using a random-zero mercury sphygmoman-
ometer, after 5 min resting, with the auscultation site at heart
level, a peak inflation level of 30 mm Hg above radial pulse
disappearance, and a cuff-deflation rate of 2–3 mm Hg/s.
Values were recorded to the nearest even digit. Heart rate
was recorded simultaneously, and systolic and diastolic
blood pressure was calculated as the mean of the two
measurements.
Genotyping of the DNA sequence variant in exon 4 was
carried out by PCR and restriction enzyme digestion.
Genomic leukocyte DNA (150 ng in a final volume of 10
Al) was amplified by PCR (annealing temperature: 56 jC)
using primers described previously [4]. The PCR reaction
product was digested at 37 jC for 3–4 h with 2 U of the
restriction enzyme EclHK1, and the fragments were sepa-
rated on a 3% agarose gel.
All statistical analyses were performed using SPSS for
Windows, release 10.0 (SPSS Inc., Chicago, IL). P values
are two-sided throughout, and a P<0.05 was considered
significant. Analyses were carried out with the General
Linear Model, with genotype as independent factor and
BMI and WHR as covariates whenever appropriate. All P
values were adjusted for multiple tests by using the Spjot-
voll–Stoline post hoc correction [8].
3. Results and discussion
The frequency of the Ala allele was 0.56 and that of the
Val allele 0.44. The observed genotype frequencies were
29.3%, 54.2% and 16.5% for Ala/Ala, Ala/Val and Val/Val,
respectively. Genotype frequencies were in a Hardy–Wein-
berg equilibrium (v2=1.6, df=2). The allelic frequencies are
in accordance with those observed in other studies on
Caucasian populations [9,10].
In the present study, there were no significant differences
between the genotype groups with respect to phenotypes of
obesity (BMI) and body fat distribution (WHR and abdomi-
nal sagittal diameter). Interestingly, the UCP2 knock-out
mice is neither obese nor resistant to diet-induced obesity
[11]. In fact, these mice have a normal body temperature
regulation, suggesting that UCP2 is not vital in the main-
tenance of normal body weight [11].
However, it has been recently shown that UCP2-deficient
ob/ob mice have increased serum insulin levels, and greatly
decreased levels of glycemia [12]. In contrast, the results of
our study indicate no significant difference in serum insulin
levels and fasting glucose, either before or after adjusting
for BMI and WHR, among the genotypes of UCP2
Ala55Val. Moreover, our data indicate no significant differ-
ences between the genotype groups regarding salivary
cortisol, testosterone, insulin-like growth factor I, leptin,
serum lipids and blood pressure (Table 1). Similar findings
have previously been reported in another Swedish sample
[10].
Although one study related the Ala55Val polymorphism
to measures of energy expenditure [5], the majority of
studies do not support a functional impact of the Ala55Val
polymorphism on polygenic obesity or Type 2 diabetes [1].
In conclusion, the Ala55Val UCP2 SNP is not associated
with any of the phenotypic features of the Metabolic
Syndrome in a general Swedish population of middle-aged
men. The Ala55Val variant might, however, influence
different components of the Metabolic Syndrome in other
ethnic groups.
Table 1
Differences in anthropometric, endocrine, metabolic and circulatory
measurements between genotypes of the Ala55Val SNP in exon 4 of the
UCP2 gene
Genotypes
Ala55Ala
(n=78)
Ala55Val
(n=144)
Val55Val
(n=44)
BMI (kg/m2) 26.5F4.2 26.1F3.8 25.7F3.8
WHR 0.94F0.09 0.94F0.06 0.93F0.06
Abdominal sagittal
diameter (cm)
22.8F4.0 22.7F3.5 22.3F3.5
Dexamethasone
suppression test (nmol/l)
11.3F4.4 12.1F5.7 13.2F5.5
Testosterone (nmol/l) 19.5F5.2 19.8F5.6 19.6F5.7
Insulin-like growth
factor I (Ag/l)
214.6F67.9 199.5F64.7 209.6F61.1
Leptin (Ag/l) 6.3F4.7 6.2F4.2 5.7F3.8
Fasting insulin (mU/l) 14.2F14.0 11.4F7.0 14.2F14.5
Fasting glucose (mmol/l) 4.5F1.0 4.6F0.9 4.6F1.2
Triglycerides (mmol/l) 1.8F1.1 1.8F1.1 1.7F0.9
Total cholesterol (mmol/l) 6.1F1.1 6.2F1.0 6.2F1.3
High-density lipoprotein
cholesterol (mmol/l)
1.3F0.3 1.2F0.3 1.3F0.4
Low-density lipoprotein
cholesterol (mmol/l)
4.0F1.0 4.1F1.0 4.2F1.2
Systolic blood pressure
(mm Hg)
130.3F16.8 129.4F18.6 128.2F15.2
Diastolic blood pressure
(mm Hg)
83.7F9.4 83.8F11.5 82.5F8.9
Heart rate (beats/min) 68.8F10.8 68.0F10.0 72.2F11.2
Data (meanFSD) were adjusted for BMI and WHR when appropriate. All
P values are > 0.20.
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